瑞舒伐他汀在纯合子家族性高胆固醇血症儿童中的疗效及其与基因突变的关系
该随机双盲交叉研究评估瑞舒伐他汀20 mg对比安慰剂在纯合子家族性高胆固醇血症(HoFH)儿童中的LDL-C疗效。14例随机、13例完成,瑞舒伐他汀较安慰剂平均降低LDL-C 85.4 mg/dl(22.3%),p=0.005,疗效与年龄、依折麦布或血浆置换使用无关,且与LDL受体突变类型相关。
要点
- 瑞舒伐他汀20 mg在HoFH儿童中较安慰剂显著降低LDL-C达22.3%。
- 疗效不受年龄、依折麦布或血浆置换使用影响,维持12周。
- LDL-C降低幅度与LDL受体突变缺陷程度相关。
核心结论
- 瑞舒伐他汀20 mg单用或联合依折麦布和/或血浆置换在HoFH儿童中安全有效降低LDL-C。
- 儿童与成人的LDL-C反应与潜在基因突变相关。
研究设计与样本
- 随机、双盲、12周交叉研究,瑞舒伐他汀20 mg对比安慰剂,随后12周开放标签瑞舒伐他汀。
- 筛查20例,随机14例,完成13例;平均年龄10.9岁,8例使用依折麦布,7例使用血浆置换。
主要发现
- 安慰剂组平均LDL-C为481 mg/dl(范围229至742 mg/dl),瑞舒伐他汀组为396 mg/dl(范围130至700 mg/dl)。
- 平均差异为85.4 mg/dl(22.3%),p=0.005。
- 疗效与年龄或依折麦布/血浆置换使用无关,并维持12周。
- 不良事件少且不严重。
- 2个缺陷型LDL受体突变者平均LDL-C降低23.5%(p=0.0044),2个阴性突变者降低14%(p=0.038)。
临床怎么用
- 瑞舒伐他汀20 mg可考虑用于HoFH儿童,单用或联合依折麦布和/或血浆置换。
- 治疗反应可能因LDL受体突变类型而异。
局限性
- 样本量小(随机14例,完成13例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Homozygous familial hypercholesterolemia (HoFH), a rare genetic disorder, is characterized by extremely elevated levels of low-density lipoprotein cholesterol (LDL-C) and accelerated atherosclerotic cardiovascular disease. Statin treatment starts at diagnosis, but no statin has been formally evaluated in, or approved for, HoFH children. OBJECTIVES: The authors sought to assess the LDL-C efficacy of rosuvastatin versus placebo in HoFH children, and the relationship with underlying genetic mutations. METHODS: This was a randomized, double-blind, 12-week, crossover study of rosuvastatin 20 mg versus placebo, followed by 12 weeks of open-label rosuvastatin. Patients discontinued all lipid-lowering treatment except ezetimibe and/or apheresis. Clinical and laboratory assessments were performed every 6 weeks. The relationship between LDL-C response and genetic mutations was assessed by adding children and adults from a prior HoFH rosuvastatin trial. RESULTS: Twenty patients were screened, 14 randomized, and 13 completed the study. The mean age was 10.9 years; 8 patients were on ezetimibe and 7 on apheresis. Mean LDL-C was 481 mg/dl (range: 229 to 742 mg/dl) on placebo and 396 mg/dl (range: 130 to 700 mg/dl) on rosuvastatin, producing a mean 85.4 mg/dl (22.3%) difference (p = 0.005). Efficacy was similar regardless of age or use of ezetimibe or apheresis, and was maintained for 12 weeks. Adverse events were few and not serious. Patients with 2 defective versus 2 negative LDL receptor mutations had mean LDL-C reductions of 23.5% (p = 0.0044) and 14% (p = 0.038), respectively. CONCLUSIONS: This first-ever pediatric HoFH statin trial demonstrated safe and effective LDL-C reduction with rosuvastatin 20 mg alone or added to ezetimibe and/or apheresis. The LDL-C response in children and adults was related to underlying genetic mutations. (A Study to Evaluate the Efficacy and Safety of Rosuvastatin in Children and Adolescents With Homozygous Familial Hypercholesterolemia [HYDRA]; NCT02226198).
引用
- Stein EA, Dann EJ, Wiegman A, et al. Efficacy of Rosuvastatin in Children With Homozygous Familial Hypercholesterolemia and Association With Underlying Genetic Mutations. J Am Coll Cardiol. 2017. PMID: 28838366. doi:10.1016/j.jacc.2017.06.058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。